Clinical trial · Observational
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinincal data and pathological specimens from patients who had undergone at least one radioactive iodine-131 (\^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected (approximately 30-50 cases each in the \^131I treatment-responsive group vs. the \^131I treatment-resistant group). Patients in the \^131I treatment-resistant group underwent \^18F-Trop2 PET-CT imaging. Inclusion criteria: 1. History of total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma (PTC); 2. At least one course of \^131I internal radiotherapy. Exclusion criteria: 1. Presence of other severe comorbidities; 2. Incomplete clinical or follow-up data. The clinicopathological characteristics and Trop2 expression levels in tissue samples were compared between the \^131I treatment-responsive group and the \^131I treatment-resistant group. Within the \^131I treatment-resistant group, comparisons were made between the rapidly progressing subgroup and the stable-disease subgroup under TSH-suppressive therapy in terms of clinicopathological features, tissue Trop2 expression levels, and SUVmax of metastatic lesions on \^18F-Trop2 PET-CT imaging. Factors influencing progression-free survival and overall survival in \^131I-resistant patients were analyzed.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| I-131 | — | UNRESOLVED | — |
| PTC | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
| Trop2 | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radioiodine-131 therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- RAI responder
- description
- The ¹³¹I treatment-responsive group was defined as patients who achieved successful radioactive iodine therapy (i.e., lesions disappeared or showed no long-term progression after radioiodine uptake).
- interventionNames
- Radiation: radioiodine-131 therapy
- label
- RAI nonresponder
- description
- The ¹³¹I treatment-resistant group was defined as patients meeting any of the following criteria: No radioiodine uptake in metastatic tissues during the first ¹³¹I treatment, with insignificant decrease or an increase in serum Tg levels before and after therapy; Partial lesions exhibit radioiodine uptake while others showed no uptaking; Progressive metastatic disease despite evident radioiodine uptake.
- interventionNames
- Radiation: radioiodine-131 therapy
Primary outcomes (1)
- measure
- Tumor size;
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria:( 1) History of total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma (PTC); (2) At least one course of \^131I internal radiotherapy. Exclusion Criteria:(1) Presence of other severe comorbidities; (2) Incomplete clinical or follow-up data.
References
Publications (0)
Data not yet available